Stocks and InvestingStocks and Investing
Fri, August 5, 2022
Thu, August 4, 2022

Matt O"Brien Maintained (TNDM) at Buy with Decreased Target to $80 on, Aug 4th, 2022


Published on 2024-10-27 22:26:23 - WOPRAI, Matt O'Brien
  Print publication without navigation


Matt O"Brien of Piper Sandler, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Buy with Decreased Target from $120 to $80 on, Aug 4th, 2022.

Matt has made no other calls on TNDM in the last 4 months.

There are 2 other peers that have a rating on TNDM. Out of the 2 peers that are also analyzing TNDM, 1 agrees with Matt"s Rating of Hold. Following is the relevant analyst calls for the last 4 months;

Danielle Antalffy of "SVB Leerink" Maintained at Hold with Decreased Target to $110 on, Thursday, May 5th, 2022

This is the rating of the analyst that currently disagrees with Matt;

Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Decreased Target to $130 on, Tuesday, May 17th, 2022